Functional evidence for biased inhibition of G protein signaling by YM-254890 in human coronary artery endothelial cells.
Qianman Peng, Saud Alqahtani, Mohammed Zahid A Nasrullah, Jianzhong Shen
Author Information
Qianman Peng: Department of Drug Discovery & Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, 36849, USA.
Saud Alqahtani: Department of Drug Discovery & Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, 36849, USA.
Mohammed Zahid A Nasrullah: Department of Drug Discovery & Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, 36849, USA.
Jianzhong Shen: Department of Drug Discovery & Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, 36849, USA. Electronic address: jzs0019@auburn.edu.
Small molecular chemicals targeting individual subtype of G proteins including Gs, Gi/o and Gq has been lacking, except for pertussis toxin being an established selective peptide inhibitor of the Gi/o protein. Recently, a cyclic depsipeptide compound YM-254890 isolated from culture broth of Chromobacterium sp. was reported as a selective inhibitor for the Gq protein by blocking GDP exchange of GTP on the α subunit of Gq complex. However, functional selectivity of YM-254890 towards various G proteins was not fully characterized, primarily due to its restricted availability before 2017. Here, using human coronary artery endothelial cells as a model, we performed a systemic pharmacological evaluation on the functional selectivity of YM-254890 on multiple G protein-mediated receptor signaling. First, we confirmed that YM-254890, at 30 nM, abolished UTP-activated P2Y receptor-mediated Ca signaling and ERK1/2 phosphorylation, indicating its potent inhibition on the Gq protein. However, we unexpectedly found that YM-254890 also significantly suppressed cAMP elevation and ERK1/2 phosphorylation induced by multiple Gs-coupled receptors including β-adrenegic, adenosine A and PGI receptors. Surprisingly, although YM-254890 had no impact on CXCR4/Gi/o protein-mediated suppression of cAMP production, it abolished ERK1/2 activation. Further, no cellular toxicity was observed for YM-254890, and it neither affected A23187- or thapsigargin-induced Ca signaling, nor forskolin-induced cAMP elevation and growth factor-induced MAPK signaling. We conclude that YM-254890 is not a selective inhibitor for Gq protein; instead, it acts as a broad-spectrum inhibitor for Gq and Gs proteins and exhibits a biased inhibition on Gi/o signaling, without affecting non-GPCR-mediated cellular signaling.
